JP2025517634A5 - - Google Patents
Info
- Publication number
- JP2025517634A5 JP2025517634A5 JP2024564833A JP2024564833A JP2025517634A5 JP 2025517634 A5 JP2025517634 A5 JP 2025517634A5 JP 2024564833 A JP2024564833 A JP 2024564833A JP 2024564833 A JP2024564833 A JP 2024564833A JP 2025517634 A5 JP2025517634 A5 JP 2025517634A5
- Authority
- JP
- Japan
- Prior art keywords
- ray powder
- powder diffraction
- diffraction pattern
- peaks
- egfr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263338371P | 2022-05-04 | 2022-05-04 | |
| US63/338,371 | 2022-05-04 | ||
| PCT/US2023/020925 WO2023215431A1 (en) | 2022-05-04 | 2023-05-04 | Salt and crystal forms of an epidermal growth factor receptor inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025517634A JP2025517634A (ja) | 2025-06-10 |
| JP2025517634A5 true JP2025517634A5 (enExample) | 2026-05-12 |
Family
ID=86688767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024564833A Pending JP2025517634A (ja) | 2022-05-04 | 2023-05-04 | 上皮増殖因子受容体阻害剤の塩形態及び結晶形態 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250282761A1 (enExample) |
| EP (1) | EP4519254A1 (enExample) |
| JP (1) | JP2025517634A (enExample) |
| KR (1) | KR20250012078A (enExample) |
| CN (1) | CN119923392A (enExample) |
| AU (1) | AU2023265064A1 (enExample) |
| CA (1) | CA3251624A1 (enExample) |
| IL (1) | IL316663A (enExample) |
| MX (1) | MX2024013485A (enExample) |
| TW (1) | TW202409016A (enExample) |
| UY (1) | UY40256A (enExample) |
| WO (1) | WO2023215431A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024097270A1 (en) * | 2022-11-01 | 2024-05-10 | Blueprint Medicines Corporation | Egfr inhibitors for treatment of cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113493419A (zh) * | 2020-03-18 | 2021-10-12 | 南京药石科技股份有限公司 | Egfr酪氨酸激酶抑制剂及其用途 |
| CN113493420B (zh) * | 2020-03-18 | 2025-04-25 | 南京迈晟科技有限责任公司 | Egfr酪氨酸激酶抑制剂及其用途 |
| IL302457A (en) * | 2020-10-30 | 2023-06-01 | Blueprint Medicines Corp | Pyrimidine compounds, preparations and their medical applications |
| CA3196857A1 (en) * | 2020-10-30 | 2022-05-05 | Gurulingappa Hallur | Pyrimidine compounds, compositions, and medicinal applications thereof |
-
2023
- 2023-05-04 EP EP23728478.1A patent/EP4519254A1/en active Pending
- 2023-05-04 US US18/862,859 patent/US20250282761A1/en active Pending
- 2023-05-04 CN CN202380051632.8A patent/CN119923392A/zh active Pending
- 2023-05-04 IL IL316663A patent/IL316663A/en unknown
- 2023-05-04 TW TW112116649A patent/TW202409016A/zh unknown
- 2023-05-04 UY UY0001040256A patent/UY40256A/es not_active Application Discontinuation
- 2023-05-04 AU AU2023265064A patent/AU2023265064A1/en active Pending
- 2023-05-04 WO PCT/US2023/020925 patent/WO2023215431A1/en not_active Ceased
- 2023-05-04 KR KR1020247040290A patent/KR20250012078A/ko active Pending
- 2023-05-04 CA CA3251624A patent/CA3251624A1/en active Pending
- 2023-05-04 JP JP2024564833A patent/JP2025517634A/ja active Pending
-
2024
- 2024-10-31 MX MX2024013485A patent/MX2024013485A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI619694B (zh) | 用於製備喹啉衍生物之方法 | |
| TWI309647B (enExample) | ||
| CN110294741B (zh) | 用于制备抗癌剂al3818、其结晶形式和其盐的方法 | |
| TWI640509B (zh) | 製造喹啉化合物之方法及包含該化合物之醫藥組合物 | |
| ES2402419T3 (es) | Polimorfos de un inhibidor de C-MET/HGFR | |
| JPH05262762A (ja) | インドール−３イル−アルキルピペラジンの抗偏頭痛４−ピロミジニル及びピリジニル誘導体 | |
| EP2740729B1 (en) | Quinazoline derivative, composition having the derivative, and use of the derivative in preparing medicament | |
| JP2021524835A5 (enExample) | ||
| JP2022526438A5 (enExample) | ||
| HRP20140908T1 (hr) | Novi polimorfni oblici hidrokloridne soli 3-(1-{3-[5-(1-metil-piperidin-4ilmetoksi)-pirimidin-2-il]-benzil}-6-okso-1,6-dihidro-piridazin-3-il)-benzonitrila i postupci njihove proizvodnje | |
| JP2024534517A5 (enExample) | ||
| JPWO2002066445A6 (ja) | キナゾリン誘導体 | |
| US8846706B2 (en) | Crystalline form K of imatinib mesylate | |
| JP2019507776A (ja) | ピリジニルアミノピリミジン誘導体のメシル酸塩の結晶形、その製造方法及びその使用 | |
| JP2024523506A5 (enExample) | ||
| DE60026877T2 (de) | Polymorphe, amorphe und hydratisierte formen von 5-chlor-3-(methansulfonylphenyl)-6'-methyl-[2,3']bipyridinyl | |
| JP2023535361A5 (enExample) | ||
| JP2018522945A5 (enExample) | ||
| JP2012526054A (ja) | 複素環置換のジフェニル尿素類誘導体及びその用途 | |
| JP2025509950A5 (enExample) | ||
| KR20190018494A (ko) | N-(2-(2-(디메틸아미노)에톡시)-4-메톡시-5-((4-(1-메틸-1h-인돌-3-일)피리미딘-2-일)아미노)페닐)아크릴아미드의 제약 염 및 그의 결정질 형태 | |
| JP2022511495A5 (enExample) | ||
| CN121532386A (zh) | 具有蛋白降解作用的芳胺类化合物 | |
| JP2023548605A5 (enExample) | ||
| JP2002507192A (ja) | ファルネシルタンパク質トランスフェラーゼの新規三環式スルホンアミドインヒビター |